About this Research Topic
Acute and chronic dysfunctions are still a concern in the transplantation field, despite significant advances in immunosuppression drug development and new protocols for preventing and treating rejection. Still, there is a need for additional sources of grafts to overcome the long waiting lists, especially in kidney transplantation; new engineering Xenorgans seem to be potential alternatives soon.
Moreover, understanding the role of new identified cells, such as MAIT and ILC, could open opportunity to better comprehend new features of graft rejection. The advance of chimeric antigen receptor (CAR) T-cells technology has the potential to develop new approaches for treating transplanted patients.
In addition to this, immunometabolism has emerged in Immunology with an extraordinary contribution to helping understand immune cells' biology. Metabolism of sugars, amino acids, and lipids, as well as metabolic products generated from the catabolism of these nutrients, have a tremendous impact on immune cell generation, differentiation, activation, and function. Targeting T-cell metabolism of glucose and/or glutamine showed improved graft survival in animals and may be used in combination with ongoing protocols for immunosuppression. It also unfastens avenues to study the mechanisms of tolerance induction to promote graft survival.
This research topic focuses on the most recent advances in the several fields of transplantation, from immunometabolism and new immune system cells that play a role in acute and chronic rejection to more recent advances in personalized therapy, as CAR T and xenotransplantation. For example, dietary products metabolized by the gut microbiota that can regulate the activation and function of dendritic cell (DC), T-cell, and B-cells. It has also reported new immune cell subsets that can promote rejection or tolerance.
Similarly, protocols targeting the combination of current immunosuppressive drugs with metabolism-targeted drugs to prevent and/or treat acute and chronic rejection. In addition, it describes how the metabolism in CAR T-cells impacts their function and potential to induce tolerance. And, finally, the use of engineering Xenorgans seems to have a rebuttal alternative for the shortage of organs.
We highly encourage the author to submit original research articles that illuminate the role of new pathways/cells and concepts involved in preventing rejection or promoting tolerance. Special attention will be also given to reviews and mini-reviews focusing on some of the topics described below:
• Immunometabolism and graft injuries.
• New immune cells subsets in graft rejection and tolerance.
• Dietary compounds and innate and acquired immune cell biology.
• Metabolism-targeting drugs as adjuvant therapy in acute and chronic rejection in solid and non-solid transplants.
• Metabolism of CAR-T directed to transplant antigens.
• Microbiota products regulating of transplant-associated dysfunctions.
• Engineering organs for transplantation.
Moreover, understanding the role of new identified cells, such as MAIT and ILC, could open opportunity to better comprehend new features of graft rejection. The advance of chimeric antigen receptor (CAR) T-cells technology has the potential to develop new approaches for treating transplanted patients.
In addition to this, immunometabolism has emerged in Immunology with an extraordinary contribution to helping understand immune cells' biology. Metabolism of sugars, amino acids, and lipids, as well as metabolic products generated from the catabolism of these nutrients, have a tremendous impact on immune cell generation, differentiation, activation, and function. Targeting T-cell metabolism of glucose and/or glutamine showed improved graft survival in animals and may be used in combination with ongoing protocols for immunosuppression. It also unfastens avenues to study the mechanisms of tolerance induction to promote graft survival.
This research topic focuses on the most recent advances in the several fields of transplantation, from immunometabolism and new immune system cells that play a role in acute and chronic rejection to more recent advances in personalized therapy, as CAR T and xenotransplantation. For example, dietary products metabolized by the gut microbiota that can regulate the activation and function of dendritic cell (DC), T-cell, and B-cells. It has also reported new immune cell subsets that can promote rejection or tolerance.
Similarly, protocols targeting the combination of current immunosuppressive drugs with metabolism-targeted drugs to prevent and/or treat acute and chronic rejection. In addition, it describes how the metabolism in CAR T-cells impacts their function and potential to induce tolerance. And, finally, the use of engineering Xenorgans seems to have a rebuttal alternative for the shortage of organs.
We highly encourage the author to submit original research articles that illuminate the role of new pathways/cells and concepts involved in preventing rejection or promoting tolerance. Special attention will be also given to reviews and mini-reviews focusing on some of the topics described below:
• Immunometabolism and graft injuries.
• New immune cells subsets in graft rejection and tolerance.
• Dietary compounds and innate and acquired immune cell biology.
• Metabolism-targeting drugs as adjuvant therapy in acute and chronic rejection in solid and non-solid transplants.
• Metabolism of CAR-T directed to transplant antigens.
• Microbiota products regulating of transplant-associated dysfunctions.
• Engineering organs for transplantation.
Keywords: Cell Metabolism, Immunometabolism, Innate Immune Cells, Graft Rejection, Xenografts, Engineering Organs, Microbiota, Metabolic-Sensing Pathways, CAR-T Cells
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
